Personal Genome Diagnostics, a Baltimore-based cancer diagnostics company, has raised $75 million to expand access to genomic testing for cancer patients.
More than ever, academic technology transfer is driving economic development.
- The number of invention disclosures — a direct measure of institutional impact on innovation — has been on the rise the past five years, growing to 25,825 in 2016.
- 16,487 new U.S. patent applications were filed, a gain of 3 percent over the prior year, and 7,021 U.S. patents were issued, up 5 percent from last year.
- The 1,024 startups formed made a direct impact on local economies with more than 73 percent of these new businesses remaining in the institution’s home state.
- Consumers and businesses benefited from 800 new products.
Originally, the BIVF was designed to put investments of up to €10-15m into early stage companies focused on immunomodulation, tissue regeneration, small and large molecule drugs, and new therapeutic modalities. The fund, launched in 2010, had a volume of €100m, 22 portfolio companies from which already one exited (Okairos).
Cancer research helmed by a Johns Hopkins radiation oncology professor is the first to receive backing from a fund backing work that might create startups.
Canton-based Personal Genome Diagnostics closed on $75 million in Series B funding and plans to triple its square footage with a new office.
WellDoc®, a leading digital health company, announced today that its clinically proven hemoglobin A1C reductions for users of its BlueStar® digital therapeutic with type 2 diabetes can translate into significant healthcare cost savings.
Silver Spring, Md.-based United Therapeutics Corp. and the FDA are duking it out in court over whether the agency improperly denied the biotechnology company seven years of orphan drug exclusivity for its drug Orenitram.
Emergent BioSolutions Inc. (NYSE:EBS) today announced the initiation of a Phase 2 dose ranging study to evaluate the safety, pharmacokinetics, and clinical benefit of FLU-IGIV, the company’s anti-influenza immune globulin being developed as an intravenous treatment for serious illness caused by influenza A infection in hospitalized patients.
Making predictions can be a tricky business. Nevertheless, Xconomy recently brought together some of San Diego’s most prominent life sciences leaders to offer their vision for what the regional biotech cluster will be like in five years.
Scott Gottlieb seems like the pharmaceutical industry’s idea of a dream FDA Commissioner, with pharma ties and an ideological bent toward deregulation.